ERBB2 and colorectal carcinoma: Intriguingly, recent studies highlight GPD1L’s tumor-suppressive potential across diverse malignancies, including HER2-negative breast cancer (20), esophageal squamous cell carcinoma (21), and gastric carcinoma (22), though its role in CRC remained unexplored prior to this investigation.